AM Medical Service, Memorial Sloan Kettering Sign Research Agreement

AI MEDICAL SERVICE INC. (AIM) has signed a joint research agreement with Memorial Sloan Kettering Cancer Center (MSK), becomeing the first Japanese company¹ to forge such an agreement with MSK in gastrointestinal endoscopy AI.
 
AIM is now working toward receiving regulatory approval in Japan for its endoscopic AI product designed to identify early-stage gastric cancer. Its collaboration with MSK will facilitate joint research to investigate the application of Japanese gastrointestinal endoscopy AI in the United States.

“I am very pleased that we have established a joint research agreement with Memorial Sloan Kettering Cancer Center (MSK), one of the world’s leading cancer research centers,” AIM CEO Dr. Tomohiro Tada said. “The research will combine our firm’s expertise in endoscopic AI with the wisdom and experience of MSK physicians like Dr. Mark A. Schattner and Dr. Makoto Nishimura to improve the diagnosis of gastrointestinal cancers in the United States. Our company will also utilize this collaborative research to accelerate our regulatory efforts in the United States, further advancing our mission to ‘Save Lives All Over the World.’”
 
Gastric cancer is the fourth most common cause of cancer death worldwide, and approximately 26,000 cases of gastric cancer are newly diagnosed in the United States each year.² By collaborating with MSK, AIM will explore the potential of using Japanese gastrointestinal endoscopy AI for clinical practice in the United States.

“We are very excited to partner with AIM on this exciting project.  Early detection of gastric cancer is a critical unmet need that has the potential to offer very significant clinical benefit to patients,” stated Schattner, chief of Gastroenterology, Hepatology & Nutrition Service, MSK. “The image processing and analysis developed by AIM is very promising and we look forward to refining it and incorporating it into clinical care to improve our patients’ outcomes,”  

AI Medical Service (AIM) is a Tokyo-based medtech company developing endoscopic AI technology, engaging in joint research with more than 100 medical institutions. 

References 
¹ As of July 2023, based on company research.
² International Agency for Research on Cancer “Cancer Today” [Accessed 2023/8/16]